Bionpharma is dedicated to serving diverse needs. We specialize in researching, developing, and manufacturing generic drugs and over-the-counter products. Discover more about our manufacturing and R&D facilities. Bionpharma has been selling a collection of OTC products on Amazon under the A+ Health brand since 2019.

Bionpharma operates as a pharmaceutical company specializing in the development of generic pharmaceutical products. We manufacture, market, and distribute over 50 drugs in the US and international markets. Additionally, we partner with other pharmaceutical companies for the in-licensing and out-licensing of generic and over-the-counter products.

2007年10月24日 · Bionpharma Inc. manufactures, markets and/or distributes more than 47 drugs in the U.S.

2017年12月8日 · BION-1301 is a first-in-class humanized antibody targeting APRIL (TNFSF13). We demonstrated that BION-1301 inhibits proliferation and survival of tumor cells and alleviates both APRIL-mediated drug resistance and immune …

Background: BION-1301 (BION) is first in class humanized monoclonal antibody directed against a proliferation-inducing ligand (APRIL) for treatment of relapsed/refractory (R/R) multiple myeloma (MM).

Launched in 2014, BionPharma was founded by a team of executives and professionals with years of cumulative experience in the generics industry. Bionpharma’s goals are to develop and commercialize affordable quality generics and building strong and effective partnerships.

2016年12月2日 · In vivo, BION-1301 was shown to suppress human APRIL induced T cell-independent B cell responses to NP-Ficoll. Biophysical and functional experiments indicated that BION-1301 recapitulated all characteristics of the mouse parental antibody hAPRIL.01A.

2022年11月16日 · BION-1301是结合并阻断增殖诱导配体（APRIL）的新型人源化单克隆抗体（mAb），具备潜在IgA肾病疾病修饰机制 （disease-modifying MOA）。 APRIL结合于B细胞上的受体B细胞成熟抗原（BCMA）和跨膜激活剂及钙调亲环素配体相互作用因子（TACI），驱动IgA发生类别转换以及产生IgA的浆细胞的增殖/存活。 BION-1301通过阻断APRIL与其受体的作用，耗竭半乳糖缺陷型IgA1（Gd-IgA1）并阻断致病性免疫复合物的生成。 此次ASN中披露的中期数据 …

This inhibits the activation of both BCMA and TACI, and their downstream signaling pathways, which prevents tumor growth, tumor cell adhesion to bone marrow cells and immune suppression. Additionally, BION-1301 may reduce APRIL-induced drug …

BION-1301 EXPERIMENTAL 600mg subcutaneous administration every 2 weeks for 104 weeks DRUG BION-1301